CDRH Scorecard Metric Determination. Presentation to the Balanced Scorecard Interest Group March 17, 2005

Size: px
Start display at page:

Download "CDRH Scorecard Metric Determination. Presentation to the Balanced Scorecard Interest Group March 17, 2005"

Transcription

1 CDRH Scorecard Metric Determination Presentation to the Balanced Scorecard Interest Group March 17, 2005

2 Organizational Structure DHHS FDA Food and Drug Administration Department of Health and Human Services ORA Office of Regulatory Affairs CBER Center for Biologics Evaluation and Research CDER Center for Drug Evaluation & Research CDRH Center for Devices and Radiological Health NCTR National Center for Toxiological Research CVM Center for Veterinary Medicine CFSAN Center for Food Safety and Applied Nutrition

3 CDRH Scorecard Development: 2000 CDRH Strategic Plan 2001 Determine Strategy 2002/2003 History Performance Scorecard Implementation 2004 Initiate process to Evaluate & Refine Scorecards

4 2002: Scorecard Development Process Collect Phase: Strategic Goals Determine obligations and commitments by reviewing Department and Agency documents

5 CDRH Strategic Goals Total Product Life Cycle Apply TPLC across Center activities to promote and protect the public health Public Health Impact Measure and communicate our impact on the public health Magnet for Excellence Attract and retain a diverse workforce to accomplish our public health mission Knowledge Management Manage knowledge to support TPLC in the information age

6 Obligations and Commitments President s Management Agenda One HHS Science Review Recommendations GPRA Goals Performance Plans (Commissioner & SES)

7 Create Phase: Develop Executive & Office Scorecards Each Office reviewed their core processes and proposed metrics which would be key indicators of success Philosophy: need an indicator for every process within our Office

8 2003 CDRH Executive Scorecard Key Result Areas (KRA s): 1. Public Health Promotion 2. Public Health Protection 3. Organizational Accountability 4. Stakeholder Collaboration 5. Workforce Excellence 6. Strategic Direction

9 FY-02/03 Metric Development CDRH Executive SC - Public Health Promotion (Expedited Approvals) 1. Average total elapsed days for approval 2. Average total elapsed time for final decisions 3. # of Expedited Applications 4. Average "Public Health Impact Score" based on population affected and risk reduction 5. # of agreement, determination, and other pre- submission meetings 6. % of Investigational Device Exemptions approved in the first 30-day cycle 7. % of submissions citing guidance or recognized standards

10 Office Scorecard Average total elapsed time for approval Median total elapsed time for device application approvals (1) expedited Pre-Market Approval (PMA) originals & expedited panel track PMA Supplements, (2) expedited 510(k)s, (3) Humanitarian Device Exemptions (HDEs( HDEs).

11 FY-02/03 Metric Development CDRH Executive SC Workforce Excellence 1. % CDRH employees receiving training 2. Average # of training hours per employee 3. % of CDRH managers completing core competency requirements 4. % of CDRH employees utilizing distance learning 5. # of CDRH employees participating in leadership programs 6. External Expertise Ratio (# of external engagements/ opportunities for engagements)

12 Office Level % CDRH employees receiving training 1. Staff College programs (in-house) 2. university/college courses 3. professional training programs 4. details 5. sabbaticals 6. fellowships 7. distance learning 8. mentoring 9. professional conferences..

13 2003 Executive & Office Scorecards Cultivate Phase: Gather, display, analyze historical data Did not have systems in place to capture all proposed metrics Reported what was available instead of developing systems to capture data

14 Performance Management System Vision, Mission, Core Values, And Core Passions Refinements Review, Evaluate, And Improve Business Performance Management System Rewards And Recognition Organization-Wide Strategic Planning Process Annual Deployment Cycle Workgroup And Individual Performance Management Process Develop Organization-Wide Performance Scorecard Management Cascade Operating Plans, Budget, And Scorecard Cascading Process Foundations For Achieving Performance Results Teaming System And Skills Process Improvement System And Skills Leadership Development System And Skills Project Management System And Skills Richard Chang Associates

15 Assessed Current Reality Disconnect between Scorecard Measures and Measures used to Manage Workload MDUFMA* Goals data had to be hand calculated from numerous data queries Data systems were not Centralized which impacted on data roll-up Medical Device User Fee and Modernization Act

16 2005 CDRH Executive Scorecard Key Result Areas (KRA s): 1. Public Health Promotion 2. Public Health Protection 3. Effective Management 4. Knowledge Management & Stakeholder Collaboration 5. Workforce Excellence

17 FY-04/05 Metric Development Collect Phase: Determine and prioritize obligations and commitments by reviewing Department and Agency documents Highest priority: MDUFMA requirements GPRA Goals and other Budget Document Obligations

18 Prioritization Goal Statement $ & Strategic Plans Ag. $ FDA CDRH Ctr. Perf. Plans Com MDUFMA 1. Utilize Risk management to target inspection coverage for Class II and Class III domestic medical device manufacturers at 20% or an estimate 5,500 firms. (Also FY 05 Goal-Only the Performance Plan specifies the target percentage) #11 2. Conduct 295 domestic and foreign BIMO inspections with an emphasis on scientific misconduct, data integrity, innovative products, and vulnerable populations. (Also FY 05 Goal) # Complete Review and Decision on premarket FY 2004 actions defined in the MDUFMA Legislation (MDUFMA) 4. Work with Stakeholders to implement MDUFMA. This will include providing MDUFMA training by December (MDUFMA)

19 FY-04/05 Metric Development CDRH Executive SC - Public Health Promotion 1. % on-time decisions and actions 2. % of Investigational Device Exemptions approved in the first 30-day cycle 3. % on-time consults

20 FY-04/05 Metric Development CDRH Executive SC Workforce Excellence 1. Average # of training hours per employee (limited to formal training & conferences) 2. # employees meeting training target 3. % of CDRH managers completing core competency requirements 4. % of operational dollars used for external expertise

21 Utilized the Performance Management System Concept to Assign Resources and Track Progress Project Management Developed Milestones Automate: target funds toward modifying or developing systems to capture high priority metrics Centralize Data Systems: internal benchmarking to develop efficient and productive systems

22 Lessons Learned Assess what is important to Stakeholders & Customers Periodic & Systematic Review Prioritize Systematic Implementation

23 Questions? Questions Comments? Frances A. Benedict

FDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010

FDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010 FDA Nanotechnology Regulatory Science Program Science Board Presentation August 2010 FDA Nanotechnology Task Force Carlos Peña, PhD Office of the Commissioner & Subhas Malghan, PhD Center for Devices and

More information

Navigating the FDA, and understanding Medical Device Preemption. Special Counsel Foulston Siefkin

Navigating the FDA, and understanding Medical Device Preemption. Special Counsel Foulston Siefkin Navigating the FDA, and understanding Medical Device Preemption Presented by Cydney Boler Special Counsel Foulston Siefkin cboler@foulston.com 913-253-2158 March 9, 2010 A bit of Legalese upfront: The

More information

Medical Device Labeling HealthPack 2004 Program

Medical Device Labeling HealthPack 2004 Program Medical Device Labeling HealthPack 2004 Program Elizabeth Kempen Overview Regulatory Agencies and Pathways Labeling Regulations General Medical Device Labeling Requirements Electronic Labeling FDA s Current

More information

Regulatory Approach to Nanotechnology-Based Drugs For Animals

Regulatory Approach to Nanotechnology-Based Drugs For Animals Regulatory Approach to Nanotechnology-Based Drugs For Animals Steven Fleischer, DVM CSL/JIFSAN Joint Symposium on Food Safety and Nutrition: Nanotechnology in Foods and Cosmetics June 28, 2007 Introduction

More information

Tina Morrison, Ph.D. Chair, Committee on Modeling and Simulation Office of the Chief Scientist U.S. Food and Drug Administration

Tina Morrison, Ph.D. Chair, Committee on Modeling and Simulation Office of the Chief Scientist U.S. Food and Drug Administration Tina Morrison, Ph.D. Chair, Committee on Modeling and Simulation Office of the Chief Scientist U.S. Food and Drug Administration Tina.Morrison@fda.hhs.gov Joseph Pellettiere Overview FDA s Strategic Plan

More information

The Role of Chemists in the FDA Drug Approval Process

The Role of Chemists in the FDA Drug Approval Process The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization

More information

FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond

FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond Jeff Shuren, MD, JD Center for Devices and Radiological Health U.S. Food and Drug Administration May 4, 2017 1

More information

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institute

More information

FDA Drug Compliance. Pepe Rodriguez-Perez, PhD Business Excellence Consulting Inc / BEC Spain SL.

FDA Drug Compliance. Pepe Rodriguez-Perez, PhD Business Excellence Consulting Inc / BEC Spain SL. FDA Drug Compliance Presented by Pepe Rodriguez-Perez, PhD Business Excellence Consulting Inc / BEC Spain SL www.calidadpr.com email pepe@calidadpr.com Agenda 1. FDA s Strategic Priorities 2014-18 2. CDER

More information

WORKGROUP-LEVEL OVERVIEW. What You Will Learn. What You Will Apply To Your Workgroup

WORKGROUP-LEVEL OVERVIEW. What You Will Learn. What You Will Apply To Your Workgroup INTRODUCTION TO PERFORMANCE SCORECARDS WORKGROUP-LEVEL OVERVIEW What You Will Learn 1. By implementing Performance Scorecards, you are adopting an organized, proven method of defining key business outcomes

More information

Enhancing Staff Training for New Medical Device Reviewers

Enhancing Staff Training for New Medical Device Reviewers Enhancing Staff Training for New Medical Device Reviewers Carole C. Carey, BSEE, MEng. carole.carey@fda.hhs.gov Center for Devices and Radiological Health U.S. Food and Drug Administration TOPICS Addressing

More information

The FDA/CDRH Perspective in the Regulation of Surgical Mesh

The FDA/CDRH Perspective in the Regulation of Surgical Mesh The FDA/CDRH Perspective in the Regulation of Surgical Mesh David Krause, Ph.D., Branch Chief Plastic & Reconstructive Surgery Branch Division of Surgical, Orthopedic & Restorative Devices Office of Device

More information

Statistical Computing Challenges at FDA. Paul Schuette, Ph.D. Scientific Computing Coordinator Office of Biostatistics FDA/CDER/OTS

Statistical Computing Challenges at FDA. Paul Schuette, Ph.D. Scientific Computing Coordinator Office of Biostatistics FDA/CDER/OTS Statistical Computing Challenges at FDA Paul Schuette, Ph.D. Scientific Computing Coordinator Office of Biostatistics FDA/CDER/OTS What does the FDA do? FDA is responsible for protecting the public health

More information

STRATEGIC PLAN. Tier 2 Strategic Planning

STRATEGIC PLAN. Tier 2 Strategic Planning STRATEGIC PLAN Tier 2 Strategic Planning December 2018 Tier 2 Strategic Planning All Tier 2 plans replicate the balanced scorecard framework and involve a strategy map. Two formats may be used for a Tier

More information

My Experiences as an FDA Statistician

My Experiences as an FDA Statistician My Experiences as an FDA Statistician Yeh-Fong Chen, Ph.D. FDA/CDER/OB/DB3 CBA 2016-2017 Workshop series-3 Dec. 18, 2016 Disclaimer This presentation reflects the views of the author and should not be

More information

Inspection Prioritization

Inspection Prioritization FDA s Risk Toolbox: Inspection and Sampling Prioritization January 2011 Amy Barringer Division Director, Field Programs and Guidance FDA/CFSAN/Office of Compliance Inspection Prioritization 2 1 BACKGROUND

More information

FDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives

FDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives FDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives Katherine Donigan, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA Life Science Tennessee Annual Conference

More information

UNIVERSITY OF COLORADO DEPARTMENT OF INTERNAL AUDIT 2018 AUDIT PLAN As of June 1, 2017

UNIVERSITY OF COLORADO DEPARTMENT OF INTERNAL AUDIT 2018 AUDIT PLAN As of June 1, 2017 UNIVERSITY OF COLORADO DEPARTMENT OF INTERNAL AUDIT 2018 AUDIT PLAN As of June 1, 2017 Table of Contents I. Purpose 1 II. Internal Audit s Role, Objectives and Operational Strategy 1 III. Challenges and

More information

Cascading the BSC Using the Nine Steps to Success

Cascading the BSC Using the Nine Steps to Success Cascading the BSC Using the Nine Steps to Success The Balanced Scorecard Institute uses a proven, disciplined framework, Nine Steps to Success, to systematically develop, implement, and sustain a strategic

More information

VISION, MISSION, VALUES

VISION, MISSION, VALUES VISION, MISSION, VALUES Vision Statement: Through a combination of best practices and well established strategic partnerships, the Department of Human Resources will recruit, develop, and support the diverse

More information

FDA Regulatory Updates: Related to Cancer Immunotherapy

FDA Regulatory Updates: Related to Cancer Immunotherapy FDA Regulatory Updates: Related to Cancer Immunotherapy Society for Immunotherapy of Cancer (SITC) Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular, Tissue and Gene Therapies, FDA, CBER Date:

More information

FY2018 FY2021 Strategic Plan

FY2018 FY2021 Strategic Plan FY2018 FY2021 Strategic Plan It is the mission of the City of Virginia Beach Emergency Communications and Citizen Services operations and administration to provide efficient, accurate, professional processing

More information

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health 21 st Century Cures Implementation Establish Breakthrough Device Pathway Change

More information

CDER Keynote Address. Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA. AAM GRx+Biosims Conference September 5, 2018

CDER Keynote Address. Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA. AAM GRx+Biosims Conference September 5, 2018 CDER Keynote Address Patrizia Cavazzoni M.D. Deputy Center Director for Operations CDER/FDA AAM GRx+Biosims Conference September 5, 2018 1 Outline CDER s modernization roadmap Initiatives to facilitate

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Achieving Performance Excellence

Achieving Performance Excellence Achieving Performance Excellence Baldrige 101 Workshop ASQ Professional Development Summit Today s Discussion Introduce the Baldrige framework Value and Benefits of Baldrige Regional Program MN, ND & SD

More information

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements. H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO

More information

Voluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program?

Voluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program? Voluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program? Cisco Vicenty Case for Quality Program Manager Center for Devices and Radiological Health U.S. Food and Drug Administration,

More information

Association of Food & Drug Officials (AFDO) Drug and Device Session. June 5, 2012

Association of Food & Drug Officials (AFDO) Drug and Device Session. June 5, 2012 Association of Food & Drug Officials (AFDO) June 5, 2012 Drug and Device Session Presentation by: CAPT Domenic J. Veneziano Director, Division of Import Operations and Policy PRESENTATION OVERVIEW I. General

More information

Food and Drug Administration (FDA) 101

Food and Drug Administration (FDA) 101 Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the

More information

Paths to Market & FDA Product Lifecycle Regulation. Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005

Paths to Market & FDA Product Lifecycle Regulation. Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005 Paths to Market & FDA Product Lifecycle Regulation Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005 FDA Organization U.S. Food & Drug Administration Headed by a Commissioner

More information

Data Transparency and Quality Metrics

Data Transparency and Quality Metrics Data Transparency and Quality Metrics Ann Ferriter Division of Analysis and Program Operations Office of Compliance Center for Devices and Radiological Health Why are we interested in transparency? What

More information

Guidance for IRBs, Clinical Investigators and Sponsors

Guidance for IRBs, Clinical Investigators and Sponsors Guidance for IRBs, Clinical Investigators and Sponsors IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is

More information

Good Governance and Anti-Corruption: The Role of Supreme Audit Institutions (SAIs)

Good Governance and Anti-Corruption: The Role of Supreme Audit Institutions (SAIs) Good Governance and Anti-Corruption: The Role of Supreme Audit Institutions (SAIs) Phillip Herr, Ph.D. Managing Director, Physical Infrastructure Issues U.S. Government Accountability Office The Vision

More information

Plans for Competency-Based Human Resources Management in KINS

Plans for Competency-Based Human Resources Management in KINS Plans for -Based Human Resources Management in KINS May 13, 2014 Young-Joon CHOI, Head Human Resources Development Department International Nuclear Safety School Contents I. Backgrounds II. What is a competency?

More information

Excellence in Action: Division of Human Resources Summary Response to the Human Resources Assessment. Division of Human Resources

Excellence in Action: Division of Human Resources Summary Response to the Human Resources Assessment. Division of Human Resources Excellence in Action: Division of Human Resources Summary to the Human Resources Assessment Division of Human Resources March 26, 2010 Introduction The Human Resources Assessment was conducted in response

More information

IPMA-CANADA INTERNATIONAL CERTIFICATION PROGRAM IPMA-CP (IN TRAINING) IPMA-CP IPMA-ACP IPMA-EX IPMA-CE

IPMA-CANADA INTERNATIONAL CERTIFICATION PROGRAM IPMA-CP (IN TRAINING) IPMA-CP IPMA-ACP IPMA-EX IPMA-CE IPMA- Canada INTERNATIONAL PROGRAM IPMA-CP (IN TRAINING) IPMA-CP IPMA-ACP IPMA-EX IPMA-CE INTERNATIONAL PROGRAM is a national human resource management association whose mission is to promote excellence

More information

Rainforest Strategies

Rainforest Strategies Rainforest Strategies British Columbia s Innovation Ecosystem 03 October 2018 Webinar: TechDev 101 1 Rainforest Strategies Innovation Frontera JoeSterling@RFS-LLP.com +1-619-206-2403 www.rfs-llp.com 27

More information

The Future of Drug Safety

The Future of Drug Safety The Future of Drug Safety IOM Committee on the Assessment of the US Drug Safety System R. Alta Charo Warren P. Knowles Professor of Law & Bioethics University of Wisconsin Charge to the Committee Examine

More information

CDRH s Inspection Strategy for 2018: How it Will Impact Your Company

CDRH s Inspection Strategy for 2018: How it Will Impact Your Company CDRH s Inspection Strategy for 2018: How it Will Impact Your Company CAPT Sean M. Boyd, MPH, USPHS Deputy Director for Regulatory Affairs CDRH Office of Compliance Patients are at the Heart of What We

More information

Disclosures 4/2/2011. No conflict of interest Not representing any organization Not a billing consultant

Disclosures 4/2/2011. No conflict of interest Not representing any organization Not a billing consultant San Francisco Radiation Oncology Conference April 2, 2011 Accelerated Partial Breast Irradiation: The Conundrum of Regulation and Reimbursement Disclosures No conflict of interest Not representing any

More information

Issues in Clinical Trial Designs for Devices

Issues in Clinical Trial Designs for Devices Issues in Clinical Trial Designs for Devices Soma Kalb, PhD Director, Investigational Device Exemption (IDE) Program Office of Device Evaluation Center for Devices and Radiological Health FDA Clinical

More information

Strategic Plan The OSC: A 21 st Century Securities Regulator

Strategic Plan The OSC: A 21 st Century Securities Regulator 2012-2015 Strategic Plan The OSC: A 21 st Century Securities Regulator 2 The Ontario Securities Commission (OSC) is the regulatory body responsible for overseeing Ontario s capital markets, which include

More information

Bipartisan Policy Center, Top Medical Innovation Priorities

Bipartisan Policy Center, Top Medical Innovation Priorities Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative

More information

Carrie McMahon, Ph.D. Center for Food Safety and Applied Nutrition Office of Food Additive Safety. October 14, 2015

Carrie McMahon, Ph.D. Center for Food Safety and Applied Nutrition Office of Food Additive Safety. October 14, 2015 Carrie McMahon, Ph.D. Center for Food Safety and Applied Nutrition Office of Food Additive Safety October 14, 2015 FDA s Oversight of Food and Feed Safety food safety requirements how food safety requirements

More information

COMBINATION PRODUCTS Inspection Readiness and Outcomes

COMBINATION PRODUCTS Inspection Readiness and Outcomes WHITE PAPER COMBINATION PRODUCTS Inspection Readiness and Outcomes Many companies think that because they have a good relationship with the FDA Center they interacted with during their submission reviews

More information

HR Excellence. Confederation of Indian Industry

HR Excellence. Confederation of Indian Industry HR Excellence HR Excellence Assessment Model 2010 Leadership Broad Parameters Human Resource Strategy HR Management & Processes People Knowledge & Competencies People well being & engagement Results Perception

More information

Future of Pharmaceutical Quality and the Path to Get There

Future of Pharmaceutical Quality and the Path to Get There Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 3rd PQRI/FDA Conference on Advancing

More information

Strategic Plan

Strategic Plan Strategic Plan 2017-2019 THE NATIONAL GRADUATE SCHOOL OF QUALITY MANAGEMENT Celebrating 20 YEARS of Quality Education This material is protected by United States copyright laws. You must treat this publication

More information

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application DRAFT GUIDANCE This guidance is being distributed for comment purposes only. Comments and suggestions regarding

More information

Building a Government Balanced Scorecard. Phase 1 - Planning

Building a Government Balanced Scorecard. Phase 1 - Planning Building a Government Balanced Scorecard Phase 1 - Planning Paul Arveson The Balanced Scorecard Institute March 2003 2003 Balanced Scorecard Institute 1 Example of a Government Balanced Scorecard Implementation

More information

Strategic & Operational Plan

Strategic & Operational Plan 2015 2017 Strategic & Operational Plan 1 Strategic Plan Vision Statement: The elimination of occupational injury and illness in Saskatchewan. Mission Statement: To ensure the execution of an integrated

More information

Update on Current FDA Policies and Priorities

Update on Current FDA Policies and Priorities Update on Current FDA Policies and Priorities Vernessa Pollard MassMEDIC FDA Update December 12, 2017 Boston Brussels Chicago Dallas Düsseldorf Frankfurt Houston London Los Angeles Miami Milan Munich New

More information

Expanding Leadership and Substantive Skills of Statistical Agency Personnel Panel Discussion

Expanding Leadership and Substantive Skills of Statistical Agency Personnel Panel Discussion Expanding Leadership and Substantive Skills of Statistical Agency Personnel Panel Discussion Lisa M. LaVange, PhD Director, Office of Biostatistics OTS/CDER/FDA FCSM Policy Seminar Washington, D.C. Dec.

More information

Role of the FDA and PDUFA in Drug Development

Role of the FDA and PDUFA in Drug Development Role of the FDA and PDUFA in Drug Development Questions to be addressed 1. What is the Food and Drug Administration and why is it important? 2. Why was the Prescription Drug User Fee Act (PDUFA) created?

More information

Guidance for Industry - Computerized Systems Used in Clinical Trials

Guidance for Industry - Computerized Systems Used in Clinical Trials Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials

More information

FAA PMIWDC LUNCHEON SERIES STRATEGIC PLANNING; WHAT, WHY, AND HOW

FAA PMIWDC LUNCHEON SERIES STRATEGIC PLANNING; WHAT, WHY, AND HOW FAA PMIWDC LUNCHEON SERIES STRATEGIC PLANNING; WHAT, WHY, AND HOW John Lever, Managing g Partner The Lever Group February 29 th, 2012 vision mission strategy performance INTRODUCTION AND SESSION OVERVIEW

More information

The Institute of Medicine FDA s Role in Ensuring Safe Food January 28, 2011 PREDICT

The Institute of Medicine FDA s Role in Ensuring Safe Food January 28, 2011 PREDICT The Institute of Medicine FDA s Role in Ensuring Safe Food January 28, 2011 PREDICT Presentation by: CDR Domenic J. Veneziano, Director, Division of Import Operations Topics PREDICT (Predictive Risk-based

More information

Metropolitan St. Louis Sewer District. Strategic Business and Operating Plan Fiscal Years

Metropolitan St. Louis Sewer District. Strategic Business and Operating Plan Fiscal Years Metropolitan St. Louis Sewer District Strategic Business and Operating Plan Fiscal Years 2013 2017 VISION STATEMENT Quality Service Always MISSION STATEMENT To protect the public s health, safety, and

More information

State of Office of Pharmaceutical Quality (OPQ) Address

State of Office of Pharmaceutical Quality (OPQ) Address State of Office of Pharmaceutical Quality (OPQ) Address Giuseppe Randazzo, M.S. Director, Office of Program and Regulatory Operations Office of Pharmaceutical Quality Center for Drug Evaluation and Research,

More information

BUSINESS ACCOMPLISHMENTS CONSUMER PROTECTION

BUSINESS ACCOMPLISHMENTS CONSUMER PROTECTION BUSINESS ACCOMPLISHMENTS 2016-2017 CONSUMER PROTECTION Goal: To regulate and enforce the legislation by which the Ontario travelling public can be confi dent in their travel purchases, including working

More information

Government-Wide Diversity and Inclusion Strategic Plan 2011

Government-Wide Diversity and Inclusion Strategic Plan 2011 Government-Wide Diversity and Inclusion Strategic Plan 2011 Our Nation derives strength from the diversity of its population and from its commitment to equal opportunity for all. We are at our best when

More information

STRATEGIC PLAN. FY

STRATEGIC PLAN. FY STRATEGIC PLAN FY 2017-2021 www.flynaples.com Adopted June 15, 2017 NAPLES AIRPORT AUTHORITY BOARD OF COMMISSIONERS Dick Evans Vice Chair Naples Airport began operation in 1943 as a military airfield.

More information

THE CULTURE CANVAS A Working Guide and Checklist to Support the Development of a High-Performing Culture

THE CULTURE CANVAS A Working Guide and Checklist to Support the Development of a High-Performing Culture denison TM THE CULTURE CANVAS A Working Guide and Checklist to Support the Development of a High-Performing Culture The Denison Model of High Performance A Systems Approach to Understanding and Managing

More information

IPMA-Canada Certification Program

IPMA-Canada Certification Program Program IPMA-CP (In Training) IPMA-CP IPMA-ACP IPMA-EX IPMA-CE International Personnel Management Association Canada 3333 333 Program IPMA-Canada is a national human resource management association whose

More information

November CFPB Diversity and Inclusion Strategic Plan

November CFPB Diversity and Inclusion Strategic Plan November 2016 CFPB Diversity and Inclusion Strategic Plan 2016-2020 Message from Richard Cordray Director of the CFPB At the Consumer Financial Protection Bureau (CFPB), we are dedicated to making sure

More information

The Brave New World of Medical Devices

The Brave New World of Medical Devices The Brave New World of Medical Devices December 17, 2014 BOSTON GERMANY ISRAEL www.bmtadvisors.com www.bmtcrogroup.com 1 It Is All About The Adoption More Than a Mantra David Barone December 17, 2014 www.bmtadvisors.com

More information

CERTIFICATIONS IN HUMAN RESOURCES. SPHRi TM Senior Professional in Human Resources - International TM SPHRi. Exam Content Outline

CERTIFICATIONS IN HUMAN RESOURCES. SPHRi TM Senior Professional in Human Resources - International TM SPHRi. Exam Content Outline CERTIFICATIONS IN HUMAN RESOURCES SPHRi TM Senior Professional in Human Resources - International TM 2018 SPHRi Exam Content Outline SPHRi Exam Content Outline At-a-Glance: SPHRi Exam Weighting by Functional

More information

Show value by learning to align initiatives, collecting data, and demonstrating the impact on business results. HUMAN CAPITAL. 30 T+D September 2013

Show value by learning to align initiatives, collecting data, and demonstrating the impact on business results. HUMAN CAPITAL. 30 T+D September 2013 HUMAN CAPITAL Show value by learning to align initiatives, collecting data, and demonstrating the impact on business results. 30 T+D September 2013 PHOTO: JENNI SWEITZER podcast examining INTEGRATED TALENT

More information

Organizational Change Through Metrics

Organizational Change Through Metrics Organizational Change Through Metrics Speaker: Allen Hurst and Heather Rainey Company: Improving Enterprises Website: www.improvingenterprises.com Welcome to the PMI Houston Conference & Expo 2015 Please

More information

Center for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.

Center for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review. Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA) and New Drug Review LT Renu Lal, Pharm.D. CDER Small Business and Industry Assistance Division of Drug Information

More information

PHARM 532 Regulation of Pharmaceuticals II

PHARM 532 Regulation of Pharmaceuticals II FDA s Regulatory Structuret PHARM 532 Regulation of Pharmaceuticals II Spring 2009 Center(s) for Biologics Evaluation & Research (CBER) 1 Drug Evaluation & Research (CDER) 2 Device & Radiological Health

More information

Objective Standards Of Performance

Objective Standards Of Performance Objective Standards Of Performance Introduction...1 Section A - Laboratory Leadership...2 Section B Science And Technology...5 Section C - Performance Objectives, Criteria And Measures...7 1 Environment,

More information

Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations

Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations DRAFT GUIDANCE This draft guidance document is being distributed for comment purposes only.

More information

Supply Management Three-Year Strategic Plan

Supply Management Three-Year Strategic Plan Supply Management Three-Year Strategic Plan 2010-2012 Message From the Vice President, Supply Management I am pleased to present our new three-year strategic plan for fiscal years 2010 2012. The plan

More information

GW Human Resources Strategic Plan

GW Human Resources Strategic Plan GW Human Resources Strategic Plan 2017-2021 OUR VISION We aspire to develop a diverse and engaged workforce to lead GW to excellence. OUR MISSION The mission of Human Resources is: to serve as an effective

More information

Dial-in Number: Access code: # Go to: Use the JOIN A SESSION button Enter the Access Code:

Dial-in Number: Access code: # Go to:   Use the JOIN A SESSION button Enter the Access Code: Dial-in Number: 209 647-1075 Access code: 1013004# Go to: http://www.gatherplace.net Use the JOIN A SESSION button Enter the Access Code: 8285433 This presentation may appear different on your computer

More information

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order Document issued on: [Level 2, June 15, 2009] This guidance supersedes the document issued under this

More information

Title: Review of Medical Devices Page: 1 of 5 Written by:

Title: Review of Medical Devices Page: 1 of 5 Written by: THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,

More information

FLORIDA DEPARTMENT OF HEALTH AGENCY WORKFORCE DEVELOPMENT IMPLEMENTATION PLAN

FLORIDA DEPARTMENT OF HEALTH AGENCY WORKFORCE DEVELOPMENT IMPLEMENTATION PLAN FLORIDA DEPARTMENT OF HEALTH AGENCY WORKFORCE DEVELOPMENT IMPLEMENTATION PLAN Mission To protect, promote and improve the health of all people in Florida through integrated state, county, and community

More information

LIFE SCIENCE BENCHMARKING STUDY. Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies

LIFE SCIENCE BENCHMARKING STUDY. Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies LIFE SCIENCE 01 BENCHMARKING STUDY Trends and Best Practices Based on Our Work with the US FDA and Over 0 Companies SUMMARY In this report, UL EduNeering has identified the 01/01 compliance and business

More information

Overview of USP Activities and How to Get Involved

Overview of USP Activities and How to Get Involved Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting

More information

Recommendations for Strengthening the Investigator Site Community

Recommendations for Strengthening the Investigator Site Community Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

More information

A conversation about the framework for performance excellence PERFORM LIKE A ROCK STAR!

A conversation about the framework for performance excellence PERFORM LIKE A ROCK STAR! A conversation about the framework for performance excellence PERFORM LIKE A ROCK STAR! Like Olympic athletes, pursing performance excellence in our work implies that we optimize every factor that goes

More information

Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators

Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators Journal of Diabetes Science and Technology Volume 5, Issue 2, March 2011 Diabetes Technology Society REVIEW ARTICLE Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators

More information

Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown

Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Agency-Wide FDA can perform activities necessary to address imminent threats to the safety of human

More information

Human Resources Strategic Update. Presented by Stephen Trncak October 28, 2011

Human Resources Strategic Update. Presented by Stephen Trncak October 28, 2011 Human Resources Strategic Update Presented by Stephen Trncak October 28, 2011 Agenda Past and Future for the College The End Game (Elevating the Human and Organizational Capabilities and Capacity of the

More information

CSR / Sustainability Governance and Management Assessment By Coro Strandberg President, Strandberg Consulting

CSR / Sustainability Governance and Management Assessment By Coro Strandberg President, Strandberg Consulting Introduction CSR / Sustainability Governance and Management Assessment By Coro Strandberg President, Strandberg Consulting www.corostrandberg.com November 2015 Companies which adopt CSR or sustainability

More information

FDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers

FDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers FDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers Autumn Dawn Ediger, 1, * Birgit Limbach 2 and Dieter Dannhorn 3 1 Regulatory Affairs, Clinical QM and

More information

Re: Docket No. FDA 2015-D-1580:

Re: Docket No. FDA 2015-D-1580: August 17, 2015 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2015-D-1580: Patient Preference Information Submission,

More information

Office of Pharmaceutical Quality Progress Update

Office of Pharmaceutical Quality Progress Update Office of Pharmaceutical Quality Progress Update Michael Kopcha, Ph.D., R.Ph. Director Office of Pharmaceutical Quality CDER/FDA 2017 3 rd PQRI/FDA Conference on Advancing Product Quality March 22-24,

More information

Milestones & Benchmarks

Milestones & Benchmarks 2014 Center for Communities That Care, University of Washington Phase 1: Get Started 1.1 Organize the community to begin the Communities That Care Process. Designate a single point of contact to act as

More information

DoD ENVIRONMENTAL MANAGEMENT SYSTEM (EMS) METRICS FISCAL YEARS

DoD ENVIRONMENTAL MANAGEMENT SYSTEM (EMS) METRICS FISCAL YEARS DoD ENVIRONMENTAL MANAGEMENT SYSTEM (EMS) METRICS FISCAL YEARS 2009 2011 These metrics are identical to the Federal EMS Metrics and provide the mechanism by which DoD agencies, organizations and facilities

More information

New Approach to Drug Inspections

New Approach to Drug Inspections New Approach to Drug Inspections Donald D. Ashley Director CDER Office of Compliance 2018 FDLI Annual Meeting May 4, 2018 Office of Compliance Structure Mission: The Office of Compliance shield s patients

More information

Document issued on: March 19, The draft of this document was issued on May 20, 2010.

Document issued on: March 19, The draft of this document was issued on May 20, 2010. Reprinted from FDA s website by Guidance for Industry, Third Parties and Food and Drug Administration Staff Medical Device ISO 13485:2003 Voluntary Audit Report Submission Pilot Program Document issued

More information

Murray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director

Murray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director Murray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director The National Academies Innovation Policy Forum September

More information

Charter for Enterprise Risk Management

Charter for Enterprise Risk Management for Enterprise Risk Management Prepared by: Shannon Sinclair Version: 1.2 Document Id: Date: Release Date TABLE OF CONTENTS TABLE OF CONTENTS... i 1. Background... 1 2. Objectives... 1 3. Scope... 2 3.1

More information

Developing Enterprise-Wide Measures for Tracking Performance of Acquisition Organizations

Developing Enterprise-Wide Measures for Tracking Performance of Acquisition Organizations Pittsburgh, PA 15213-3890 Developing Enterprise-Wide Measures for Tracking Performance of Acquisition Organizations Wolfhart Goethert Carnegie Mellon University Pittsburgh, PA 15213-3890 Sponsored by the

More information

Evaluating and Building Portfolio Management Maturity

Evaluating and Building Portfolio Management Maturity Evaluating and Building Portfolio Management Maturity Hostetter and Norris, UMD PM Symposium 2016 Evaluating and Building Portfolio Management Maturity Susan Hostetter and Sherri Norris U.S. Census Bureau,

More information